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S U M M A R Y
Objectives: The safety and immunogenicity of mammalian cell-derived quadrivalent inﬂuenza vaccine
(QIVc) as compared with trivalent inﬂuenza vaccines (TIV1c/TIV2c) was evaluated in children aged 4 to
<18 years.
Methods: Two thousand three hundred and thirty-three subjects were randomized 2:1:1 to receive
either one or two doses of study vaccine depending on previous vaccination status. Hemagglutination
inhibition antibody responses for all four inﬂuenza strains were performed 3 weeks after the last dose.
Reactogenicity and safety were also assessed (ClinicalTrials.gov: NCT01992107).
Results: QIVc met the non-inferiority criteria against all four vaccine strains and demonstrated
superiority for both inﬂuenza B strains over the unmatched B lineage included in the comparator
vaccines, when geometric mean titers and seroconversion rates were compared at 3 weeks after the last
vaccination. Similar percentages of subjects experienced solicited and unsolicited adverse events (AEs)
across all subgroups. Unsolicited AEs, serious AEs, medically attended AEs, and new onset chronic
disease were reported in comparable percentages of subjects in all study groups. No vaccine-related
serious AEs or deaths occurred.
Conclusions: QIVc demonstrated a similar safety proﬁle and immunogenicity responses against all four
vaccine strains without signs of immune interference on addition of an alternate lineage B strain
compared with TIV1c/TIV2c and may provide broader protection against both inﬂuenza B lineages in
children.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Inﬂuenza virus infection is a worldwide and major public health
burden causing up to 500 000 deaths each year.1 Globally, there is
an estimated annual attack rate of 5–10% in adults and 20–30% in
children, causing illness, hospitalization, and death.1 When* Corresponding author. Tel.: +1 514 631 6775x1273; fax: +1 647 8232738.
E-mail address: ahmed.abdul_mateen@novartis.com (A.A. Mateen).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).compared with the general population, children are at a high risk
of infection, particularly during epidemics, with the rate of
infection being >40% in pre-school children and 30% in school-
age children. These children are more likely to spread the inﬂuenza
infection into households and communities.2–5
The majority of inﬂuenza cases since 1977 have been caused by
the circulating inﬂuenza strains A/H1N1, A/H3N2, and B/Victoria
and B/Yamagata lineage.6 The current challenge in protecting
individuals against inﬂuenza is to provide a vaccine with an
antigenic match against the circulating strains in a given inﬂuenzaciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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through 2010–2011), the most common circulating inﬂuenza B
lineage was not that selected for the vaccine.8,9 Therefore, there
was very limited effectiveness in relation to the inﬂuenza
vaccination campaigns, as a large percentage of the disease was
caused by the inﬂuenza B strains during the epidemics. Including
one strain from each B lineage in addition to A/H1N1 and A/H3N2
strains in the seasonal inﬂuenza vaccines may increase the efﬁcacy
of the inﬂuenza vaccine.10 It is therefore warranted to include one
strain from each B lineage in addition to A/H1N1 and A/H3N2
strains in order to increase the efﬁciency of the seasonal inﬂuenza
vaccines.
Since 1985, two antigenically distinct lineages of inﬂuenza B
viruses have disseminated worldwide and there is no cross-
protection between the lineages.7 Also, there is a risk of mismatch
for the inﬂuenza B strain as only one lineage is selected for
inclusion in the currently available trivalent inﬂuenza vaccines
(TIVs).11,12 The use of quadrivalent inﬂuenza vaccines (QIVs) might
eliminate the risk of B lineage mismatch, and some QIVs have
recently been approved in the USA.13 Therefore, the use of a QIV
may lead to a decrease in the inﬂuenza burden.14
The Madin Darby canine kidney (MDCK) cell line is optimized
for inﬂuenza replication and is regarded as a well characterized
and safe cell line that adheres to Good Manufacturing Practices.15
The cell line is compliant with the US Food and Drug Administra-
tion (FDA), European Medicines Agency (EMA), and World Health
Organization (WHO) guidelines for purity, identity, and for the
absence of adventitial viruses.15 In addition, the cell line offers
advantages of ‘on-demand’ production and lack of antibiotic use.15
Because the mammalian cell lineage is closer to human cell lines,
replication of inﬂuenza viral strains in the MDCK cell line may
reduce the degree of antigen change that occurs in inﬂuenza
strains replicated in eggs. It is expected that this may produce a
better antigenic match against circulating viral strains isolated
from humans.3,16–18
The present study was designed to evaluate the safety and
immunogenicity in children aged 4 to <18 years of each of the
four inﬂuenza strains contained in the cell-derived QIV (QIVc)
vaccine as compared with the inﬂuenza strains contained in two
trivalent inactivated inﬂuenza vaccines: TIV1c and TIV2c. All three
inﬂuenza vaccines are based on the same manufacturing process
and contain the same A/H3N2 and A/H1N1 strains, but TIVc1 and
TIVc2 contain B strains of the opposite lineage: B/Yamagata and B/
Victoria, respectively; QIV contains both B strains.
2. Materials and methods
2.1. Study design and objectives
This phase III, double-blind, stratiﬁed, randomized study was
conducted at 90 sites in the USA between November 2013 and
August 2014. The study had two primary objectives: to demon-
strate non-inferiority of antibody responses post-vaccination as
measured by the ratio of geometric mean titers (GMTs) and
differences in seroconversion (SC) rates of QIVc in comparison with
TIVc against all four vaccine strains, i.e., A/H1N1, A/H3N2 and B
strain to TIV1c and the alternate B strain response to TIV2c.
Secondary objectives were to evaluate the antibody responses
against all four strains according to the Center for Biologics
Evaluation, Research and Review (CBER) criteria, to evaluate
antibody responses according to the Committee for Medicinal
Products for Human Use (CHMP) criteria against the four strains, to
demonstrate superiority of QIVc for the unmatched inﬂuenza B
strain in TIVc as assessed by GMT ratios and SC rates, and to
determine the reactogenicity and safety of all four vaccine strains.
The study was approved by institutional review boards (centralinstitutional review board and in a few cases at individual study
sites) and the study was conducted in accordance with the
Declaration of Helsinki and the principles of Good Clinical Practice.
Written informed consent was obtained from the parents/legal
guardians of all children before enrollment; assent was also
obtained from the subjects, if applicable. The study was registered
at ClinicalTrials.gov (NCT01992107).
2.2. Study subjects
Subjects were excluded for the following reasons: a recent body
temperature 38 8C (within 3 days prior to vaccination); a history
of any signiﬁcant ongoing chronic/acute illness that would
interfere with their ability to comply with study-related proce-
dures and or interfere in the evaluation of the study vaccine;
females of child-bearing potential who had not used any of the
acceptable contraceptive methods for at least 2 months prior to
study entry and/or were not willing to do so through day 60;
females who were pregnant or breast-feeding; those of child-
bearing potential with a positive or indeterminate pregnancy test;
history of any bleeding disorder; history of anaphylaxis to previous
inﬂuenza vaccination, serious vaccine reactions, or hypersensitiv-
ity to any of the vaccine components, or on exposure to latex;
received any inﬂuenza vaccination or had documented inﬂuenza
disease within the prior 6 months; history of known or suspected
congenital or acquired immunodeﬁciency or receipt of immuno-
suppressive therapy; history of known Guillain–Barre´ syndrome.
2.3. Vaccines
Each 0.5-ml dose of the investigational QIVc contained puriﬁed
viral hemagglutinin (HA) antigens, approx. 15 mg of HA for each of
the four inﬂuenza strains recommended by the WHO for the 2013/
14 inﬂuenza vaccine composition for the Northern Hemisphere
season: A/Brisbane/10/2010 (H1N1), A/Texas/50/2012 (H3N2),
B/Massachusetts/2/2012, and B/Brisbane/60/2008.
The comparator TIVc vaccines administered (TIV1c and TIV2c)
consisted of approximately 0.5 ml, which included puriﬁed viral
HA from each of the three inﬂuenza strains A/Brisbane/10/2010
(H1N1), A/Texas/50/2012 NYMC X-223A (H3N2), and B/Massa-
chusetts/02/2012 (B1) in TIV1c, recommended by the WHO for
inclusion in the trivalent vaccine composition for the 2013/2014
inﬂuenza season, and A/Brisbane/10/2010 (H1N1), A/Texas/50/
2012 NYMC X-223A (H3N2), and B/Brisbane/60/2008 (B2) in TIV2c.
The vaccines were administered in the deltoid muscle, preferably
of the non-dominant arm.
2.4. Study procedures
Subjects were stratiﬁed into two age cohorts: 4 to <9 years
and 9 to <18 years. Within the 4 to <9 years cohort, subjects
were further stratiﬁed as previously vaccinated and not previously
vaccinated. Within each age cohort, subjects were randomized by
an interactive response technology system at a pre-speciﬁed ratio
of 2:1:1 to receive QIVc or TIV1c or TIV2c. Previously vaccinated
subjects aged 4 to <9 years and 9 to <18 years received one
vaccine dose on day 1; not previously vaccinated 4 to <9-year-
old subjects received two vaccine doses, one dose each on days
1 and 29.
Safety data were collected using diary cards provided to the
subjects and/or their parents through day 29 in previously
vaccinated subjects and through day 50 for not previously
vaccinated subjects. Additional safety data were collected through
day 180 based on interviews and records provided at follow-up
visits performed in the follow-up period. Blood samples were
taken from all subjects for hemagglutination inhibition (HI) assay:
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subjects, and day 1 (pre-vaccination) and day 50 in not previously
vaccinated subjects. Any subject who showed signs of an
inﬂuenza-like illness (ILI) during the treatment period (from day
1 through 3 weeks after the subject’s last vaccination) was
evaluated by real-time reverse transcription PCR (RT-PCR) testing
of a nasopharyngeal (NP) specimen for inﬂuenza. ILI was deﬁned as
a fever of 37.8 8C and at least one additional symptom: cough,
rhinorrhea, nasal congestion, or sore throat. RT-PCR-conﬁrmed
inﬂuenza cases were excluded from the immunogenicity analysis.
2.5. Immunogenicity assessment
Antibody responses were evaluated by HI assay and were
assessed 3 weeks after vaccination (day 22 in previously
vaccinated subjects) or day 50 (not previously vaccinated subjects)
as measured by GMTs, percentage of subjects achieving SC
(seronegative at baseline, i.e., HI titer <1:10 at day 1) as a post-
vaccination HI titer 1:40, and deﬁned in subjects seropositive at
baseline (i.e., HI titer 1:10 at day 1) as a minimum of a four-fold
increase in post-vaccination HI titer and percentage of subjects
with HI titers 40.
2.6. Safety
All subjects were observed for 30 min post-vaccination and
were provided with diary cards to record solicited local or
systemic adverse events (AEs), as well as daily body temperature
measurements for the ﬁrst 7 days after vaccination. The body
temperature was measured (oral measurement was recom-
mended) via a digital thermometer provided to the parents/
guardians by the sites. The body temperature was to be recorded
at approximately the same time of day every day during this 7-day
period.
As the nature of safety data reporting differs in younger and
older pediatric populations, age-appropriate solicited AEs were
collected. Solicited local (injection site) AEs for subjects <6 years of
age included induration, erythema, ecchymosis, and tenderness,Figure 1. Study ﬂand for those >6 years of age included induration, erythema,
ecchymosis, and pain. Solicited systemic AEs for subjects <6 years
of age were change of eating habits, sleepiness, vomiting, diarrhea,
and irritability, and for subjects >6 years of age were shivering,
nausea, generalized myalgia, generalized arthralgia, headache,
fatigue, vomiting, diarrhea, and loss of appetite. All AEs and
concomitant medications data were collected for 3 weeks after the
last vaccination. Data on all serious AEs (SAEs), medically attended
AEs, AEs leading to vaccine and/or study withdrawal, new onset
chronic disease, and concomitant medication associated with
these events were collected throughout the study period.
2.7. Statistical analysis
2.7.1. Datasets
The per-protocol set (PPS) was used to analyze the non-
inferiority objective, i.e., subjects who were vaccinated and had no
major protocol deviations. For all other analyses, the full analysis
set (FAS) was used, i.e., subjects who received at least one study
vaccination and provided immunogenicity data at day 1 and day
22 (day 50 for not previously vaccinated subjects). Log10-
transformed individual HI titers measured at 3 weeks after the
last vaccination (day 22 and day 50) were modeled using the
analysis of covariance (ANCOVA) model with factors for age
cohort (4 to <9 and 9 to <18 years of age), vaccine group, and a
covariate for the log-transformed pre-vaccination antibody titer
(baseline). GMTs, GMT ratios, and associated two-sided 95%
conﬁdence intervals (CIs) were calculated based on this model.
Because of the sparse data, the center effect was not included in
the model, and vaccine by center interaction analysis was not
performed.
2.7.2. Sample size
Assuming a dropout rate and exclusions from PPS of
approximately 15%, 1176 subjects in the QIVc arm and 588 in
each of the TIV1c and TIV2c arms were to be enrolled. There was no
statistical null hypothesis associated with the safety objectives,
which were analyzed descriptively.ow diagram.
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QIVc was considered non-inferior to TIVc if the upper bound of
the two-sided 95% CI for the ratio of GMTs for HI antibody did not
exceed the non-inferiority margin of 1.5 and the difference
between SC rates did not exceed the non-inferiority margin of
10%. QIVc was considered superior if the upper bound of the two-
sided 95% CI for the ratio of GMTs for HI antibody did not exceed
the superiority margin of 1 and the difference between SC rates did
not exceed the margin of 0.
2.7.4. Immunogenicity: CBER and CHMP
Immunogenicity was evaluated according to the current CBER
criteria (CBER, 2007). These criteria are regarded as met if the
lower bound of the two-sided 95% CI for the percentage of subjects
achieving SC for HI antibody is 40% and the percentage of
subjects achieving an HI antibody titer 40 is 70% for each
vaccine strain.
CHMP criteria for an adult population were used to evaluate the
immunogenicity in subjects 4 to <18 years of age, as no speciﬁc
criteria for people <18 years were available. CHMP criteria are
regarded as met if the point estimate for the geometric mean ratioFigure 2. Non-inferiority of QIVc compared with TIV1c/TIV2c in children 4 to <18 year
non-inferiority margin. Data are shown for the per-protocol set. The error bars indicate th
was calculated as TIV1c/QIVc, whereas the B2 inﬂuenza strain ratio of GMTs and SCR was
conﬁdence interval; TIVc, mammalian cell culture-derived trivalent inﬂuenza vaccine;(GMR) is >2.5, the percentage of subjects achieving SC is >40%, and




A total of 2333 healthy subjects were enrolled and random-
ized: 1159 subjects received QIVc (819 previously vaccinated,
340 not previously vaccinated), 593 subjects received TIV1c
(420 previously vaccinated, 173 not previously vaccinated), and
581 subjects received TIV2c (400 previously vaccinated, 181 not
previously vaccinated) (Figure 1). The reasons for exclusion from
the study for FAS and PPS were: day 22 or day 50 blood draw for
previously vaccinated subject not performed or performed
outside of the speciﬁed window; vaccine not administered;
serological results were not available; ﬁrst or second (not
previously vaccinated subjects only) dose of the study vaccine
was not administered; administration of concomitant vaccine(s)
forbidden by the protocol; administration of vaccine kept outsides of age, in terms of ratio of GMTs (A), and seroconversion (B). Dashed lines indicate
e two-sided 95% CIs. The H1N1, H3N2, and B1 inﬂuenza strain ratio of GMTs and SCR
 calculated as TIV2c/QIVc. GMT, geometric mean titer; SCR, seroconversion rate; CI,
 QIVc, mammalian cell culture-derived quadrivalent vaccine.
Table 1
Summary of demographic characteristics of subjects enrolled in the study
QIVc TIV1c TIV2c
Characteristic n = 1159 n = 593 n = 581
Age, mean (SD), years 9.5 (3.8) 9.5 (3.8) 9.3 (3.7)
Sex, n (%)
Male 603 (52) 309 (52) 297 (51)
Female 556 (48) 284 (48) 284 (49)
Height, mean (SD), cm 139.4 (22.1) 139.3 (21.3) 139.0 (21.4)
Weight, mean (SD), kg 40.8 (22.0) 40.6 (20.7) 40.4 (21.0)
Race, n (%)
Asian 7 (0.6) 2 (0.3) 2 (0.3)
American Indian 4 (0.4) 4 (0.7) 6 (1.0)
Black 261 (22.5) 131 (22.1) 118 (20.3)
Caucasian 614 (53.0) 321 (54.1) 308 (53.0)
Hispanic 227 (19.6) 114 (19.2) 122 (21.0)
Native Hawaiian 5 (0.4) 1 (0.2) 5 (0.9)
Other 41 (3.5) 20 (3.4) 20 (3.4)
QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine; SD, standard
deviation.
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subject was wrongly randomized as not previously vaccinated;
randomization failure; subject did not meet entry criteria; subject
reported ILI but swab was not collected for testing for inﬂuenza;
subject with swabs testing positive for inﬂuenza; subject tested
positive for inﬂuenza during the treatment period (Figure 1).
Demographic and other characteristics were balanced across the
vaccine groups (Table 1). Ninety-six percent of subjects who
received QIVc, 95% who received TIV1c, and 96% who received
TIV2c were included in the FAS; 87% of subjects who received
QIVc, 86% who received TIV1c, and 86% who received TIV2c were
included in the PPS.
3.2. Non-inferiority
For the overall 4 to <18 years age group, at 3 weeks after the
last vaccination, the immune response to QIVc was shown to beTable 2
Percentage of subjects (95% CI) aged 4 to <18 years with seroconversion and
hemagglutination inhibition titer 1:40, and hemagglutination inhibition geomet-
ric mean titer ratios (95% CI) and differences in seroconversion (95% CI), 3 weeks
after the last vaccination. Data shown are for the full analysis set (FAS)
QIVc TIV1c/TIV2ca
A/H1N1 n = 1113 n = 566
SC 73 (70–76) 74 (70–77)
HI titer 1:40 99 (98–100) 99 (98–100)
A/H3N2 n = 1112 n = 566
SC 47 (44–50) 51 (47–55)
HI titer 1:40 100 (99–100) 99 (98–100)
B1 n = 1112 n = 566
SC 67 (64–70) 66 (61–69)
HI titer 1:40 92 (91–94) 93 (90–95)
GMR 6.15 (5.76–6.57) 2.38 (2.17–2.61)
SCR difference 67 (64–70) 33 (29–37)
B2 n = 1108 n = 566
SC 73 (70–76) 72 (68–76)
HI titer 1:40 91 (89–93) 91 (88–93)
GMR 2.12 (1.91–2.37) 8.16 (7.56–8.82)
SCR difference 73 (70–76) 26 (23–30)
CI, conﬁdence interval; QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza
vaccine; SC, seroconversion; HI, hemagglutination inhibition; GMR, geometric
mean titer ratio; SCR, seroconversion rate.
a For H1N1, H3N2, and B1 inﬂuenza strains (B/Massachusetts/02/2012) TIV1c
data are presented, whereas for B2 inﬂuenza strain (B/Brisbane/60/2008) TIV2c data
are presented. GMR: (day 22 or day 50)/(day 1). SCR difference: (% SC of TIV1c or
TIV2c)  % SC QIVc.non-inferior to TIVc in terms of GMT ratios and SC differences for
all four vaccine strains (Figure 2A, B).
3.3. Immunogenicity: CBER criteria
At day 22 or day 50, 3 weeks after the last vaccination, both
CBER immunogenicity criteria for SC (Table 2) and HI titer 1:40
(Table 2) were met in subjects aged 4 to <18 years for all four
inﬂuenza strains by the QIVc and the TIV1c/TIV2c vaccines.
3.4. Immunogenicity: CHMP criteria
The CHMP immunogenicity criteria for SC (Table 2), HI titer
1:40 (Table 2), and GMR (Table 3) were met for all four strains by
the QIVc and the TIVc vaccines in the 4 to <18 years age group.
3.5. Superiority of inﬂuenza B strain responses in QIVc
At 3 weeks after the last vaccination, the GMTs and the
percentage of subjects with SC for the unmatched B strains were
higher in the QIVc group than in the TIV1c and TIV2c groups.
Superiority of the antibody responses in the QIVc group over the
TIV1c group against the B/Victoria strain, and the TIV2c group for
the B/Yamagata strain was established (Table 2).
3.6. Safety
Reported solicited AEs were generally mild to moderate in
severity and limited to a duration of less than 7 days. The
percentages of subjects who reported solicited local AEs were
higher with a single dose of vaccine in the QIVc group than in the
TIV1c/TIV2c groups of 4 to <6 years, 6 to <9 years, and 9 to
<18 years. However, within each vaccine group there was a
general tendency towards a decrease in the percentage of subjects
with local AEs after the second vaccine dose in subjects aged 4 to
<6 years and 6 to <9 years (Table 4). A similar trend was also
observed in the percentage of subjects who reported solicited
systemic AEs in subjects aged 6 to <9 years. However, there was a
1–3% increase in the percentage of solicited systemic AEs in 4 to
<6-year-olds after the second vaccine dose in each of the vaccine
groups (Table 4).Table 3
Geometric mean titers and ratios (95% CI) in subjects aged 4 to <18 years, 3 weeks
after the last vaccination. Data shown are for the full analysis set (FAS)
QIVc TIV1c/TIV2ca
A/H1N1 n = 1113 n = 566
Baseline 93 (84–103) 98 (85–113)
Day 22 or 50 1063 (1004–1125) 1127 (1041–1221)
GMR 11 (10–13) 12 (10–13)
A/H3N2 n = 1112 n = 566
Baseline 198 (181–216) 192 (170–217)
Day 22 or 50 720 (688–754) 769 (721–820)
GMR 3.65 (3.4–3.91) 3.97 (3.59–4.38)
B1 n = 1112 n = 566
Baseline 25 (23–27) 23 (21–26)
Day 22 or 50 153 (145–163) 150 (138–163)
GMR 6.15 (5.72–6.61) 6.24 (5.64–6.91)
B2 n = 1108 n = 556
Baseline 22 (20–24) 22 (20–25)
Day 22 or 50 179 (166–193) 187 (169–208)
GMR 8.17 (7.5–8.89) 8.45 (7.5–9.53)
CI, conﬁdence interval; QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza
vaccine; GMR, geometric mean titer ratio.
a For H1N1, H3N2, and B1 inﬂuenza strains (B/Massachusetts/02/2012) TIV1c
data are presented, whereas for B2 inﬂuenza strain (B/Brisbane/60/2008) TIV2c data
are presented.
Table 4
Percentage of subjects who reported any solicited reactions within 7 days after vaccination—solicited safety set
4 to <6 years 6 to <9 years 9 to <18 years
QIVc TIV1c TIV2c QIVc TIV1c TIV2c QIVc TIV1c TIV2c
First vaccination, na 182 91 93 372 185 186 579 294 282
Any, % 65 58 57 69 72 69 71 68 61
Local, % 57 56 51 64 67 62 65 60 55
Systemic, % 28 20 18 31 36 35 40 41 33
Others, % 10 5 4 9 9 9 6 8 7
Second vaccination, n 98 39 47 205 112 116
Any, % 60 49 43 57 63 64
Local, % 53 44 36 50 57 57
Systemic, % 31 23 19 22 27 23
Others, % 4 8 2 8 7 10
QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine.
a Not previously vaccinated subjects 4 to <6 and 6 to <9 years of age received two vaccinations, and previously vaccinated subjects (4 to <6, 6 to <9, and 9 to <18
years of age) received one vaccination. In those aged 4 to <6 years and 6 to <9 years, the data from the ﬁrst vaccination include both previously vaccinated and not
previously vaccinated subjects.
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ness (4 to <6 years of age) and injection-site pain (6 to <9 and
9 to <18 years of age) across all vaccine groups (Figure 3), and the
most commonly reported solicited systemic AEs were sleepiness
(4 to <6 years of age), fatigue (6 to <9 years of age), and
headache (9 to <18 years of age) across all vaccine groups
(Figure 4). The body temperature of the majority of subjects was
within the normal range following study vaccinations.Figure 3. Percentage of subjects who reported any solicited local reactions within 7 days
years (C), by vaccine group. Cases classiﬁed as severe are illustrated by black bars within t
severity of reactions was categorized as mild, moderate, or severe, if they resulted in
respectively.A low percentage of subjects were administered analgesics and/
or antipyretics for treatment in the ﬁrst 7 days following any study
vaccination: 4 to <6 years: 8%, 5%, 3%; 6 to <9 years: 11%, 9%, 9%;
and 9 to <18 years: 4%, 7%, 5% in the QIVc, TIV1c, and TIV2c groups,
respectively.
Unsolicited AEs were reported by 24% of subjects in the QIVc and
TIV1c vaccine groups and by 27% in the TIV2c vaccine group
(Table 5). The percentages of AEs judged by the investigator as of any vaccination in age cohorts 4 to <6 years (A), 6 to <9 years (B), and 9 to <18
he total percentage of subjects reporting the respective solicited local reaction. *The
 no limitation, some limitation, or an inability to perform normal daily activities,
Figure 4. Percentage of subjects who reported solicited systemic reactions occurring within 7 days of any vaccination by vaccine group in the age cohorts of 4 to <6 years (A),
6 to <9 years (B), and 9 to <18 years (C). Cases classiﬁed as severe are illustrated by black bars within the total percentage of subjects reporting the respective solicited
systemic reaction. *The severity of reactions was categorized as mild, moderate, or severe, if they resulted in no limitation, some limitation, or an inability to perform normal
daily activities, respectively.
Table 5








Any AE, % 24 24 27
At least possibly related AE, % 5 6 5
SAE, % 1 1 <1
Medically attended AE, % 27 27 27
New onset of chronic disease, % 2 2 2
QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine; AE, adverse
event; SAE, serious adverse event.
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TIV2c groups were comparable (Table 5). SAEs were reported by
approximately 1% of subjects in the QIVc and TIV1c groups and less
than 1% in the TIV2c group. No SAE was judged as related to the study
vaccine; new onset of chronic disease was reported by 2% of subjects
in each vaccine group. No deaths were reported during the study.
4. Discussion
Inﬂuenza B causes infections in all ages, most commonly among
older children and young adults.1–6 Although the inﬂuenza B strain
is genetically more constant than inﬂuenza A, the dominant
circulating lineage of inﬂuenza B strain diverges every season. Over
the past decade, two distinct genetic lineages of inﬂuenza B strain
have circulated together, with variations occurring within each of
these two antigenically distinct lineages.10
A mismatch between the predominant inﬂuenza B lineage in
circulation and that present in the seasonal inﬂuenza vaccine has
been shown to have an adverse inﬂuence on public health. For the
given inﬂuenza seasons, 1999–2000 through 2008–2009, the
proportion of all inﬂuenza disease identiﬁed as type B has varied
from 0.4% to 46%, and the proportion of inﬂuenza B lineage strains
not represented in the TIV of a given year has varied from 0% to
98%.19 On the basis of modeling implemented by the US Centers for
Disease Control and Prevention (CDC), QIV would have resulted in
approximately 2.7 million fewer inﬂuenza cases, 21 440 fewer
hospitalizations, and 1371 fewer deaths during this same 10-year
period.14 Additionally, the CDC model supports the view that
during years in which TIV demand exceeds supply, as expected in
future seasons, the use of QIV would lessen the morbidity and
mortality associated with inﬂuenza infection.14
The current phase III, randomized, double-blind study of
children aged 4 to <18 years is the ﬁrst study in children toevaluate a mammalian cell-derived QIV. It showed that the
immune response against all four inﬂuenza strains of QIVc was
non-inferior to those for TIV1c/TIV2c (2013–2014 season) for the
strains included in the corresponding trivalent inﬂuenza vaccine.
Superiority of the QIVc vaccine compared with the unmatched
inﬂuenza B strains of the TIV1c and TIV2c vaccines was also
established. In addition, in subjects aged 4 to <18 years, QIVc met
both CBER and CHMP immunogenicity criteria (based on an adult
population) for each of the four inﬂuenza vaccine strains.
The present study data reﬂect that the QIVc inﬂuenza vaccine
demonstrates strong immune responses against all four vaccine
strains without signs of immune interference from the addition of
a second inﬂuenza B strain.
Overall, the safety proﬁle of MDCK cell-derived QIV was similar
to that of TIVc vaccines, including a similar reactogenicity proﬁle.
No safety concerns were otherwise identiﬁed. The AE data
obtained in the present study are similar to those obtained from
a previous study of the MDCK cell-derived trivalent inﬂuenza
vaccines in a healthy population aged 3 to <18 years.20
R. Hartvickson et al. / International Journal of Infectious Diseases 41 (2015) 65–7272Given the ongoing challenges of inﬂuenza control, the use of a
quadrivalent inﬂuenza vaccine is expected to reduce the burden of
inﬂuenza B in the broader population. The QIVc vaccine evaluated
in this study demonstrated an acceptable immunogenicity and
safety proﬁle in the pediatric population, one of the most
vulnerable populations affected by inﬂuenza. The production of
a QIVc vaccine from an MDCK cell line offers additional advantages
of antibiotic-free, on-demand production, and the use of a
mammalian cell line makes QIVc less prone to the risk of antigenic
drift as compared to egg-derived inﬂuenza vaccines.
In conclusion, QIVc demonstrated similar safety proﬁles and
immune responses against all four vaccine strains without signs of
immune interference on addition of an alternative lineage B strain.
QIVc offers promise as a vaccine with broader protection against
both inﬂuenza B lineages in children aged 4 to <18 years when
compared with current trivalent vaccines.
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